Stem-cell transplantation for high-risk breast cancer

New England Journal of Medicine

Volumn 349, Issue 1, 2003, Pages 80-82

  Elfenbein, Gerald J ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT;

BREAST CANCER; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; DRUG MEGADOSE; EDITORIAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; NEGRO; ONCOGENE NEU; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; SURVIVAL ANALYSIS;

EID: 0038799787     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMe030087     Document Type: Editorial

References (10)

1. Elfenbein GJ, Perkins JB, Fields KK. Breast cancer. In: Ball ED, Lister J, Law P, eds. Hematopoiedc stem cell therapy. New York: Churchill Livingstone, 2000:100-16.
2. Rodenhuis S, Bontenbal M, Beex LVAM, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7-16.
3. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapyand autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17-26.
4. Cancer Information Reference File, version 6.07. Hackensack, N.J.: Impath Information Services, February 28, 2002.
5. Strauss GM. The Mayo Lung Cohort: a regression analysis focusing on lung cancer incidence and mortality. J Clin Oncol 2002;20:1973-83.
6. Elfenbein GJ. Clinical trials and survival curves: the shape of things to come. Acta Haematol 2001;105:188-94.
7. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocola group d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-30.
8. Poynard T, Munteanu M, Ratziu V, et al. Truth survival in clinical research: an evidence-based requiem? Ann Intern Med 2002;136:888-95.
9. Tartarone A, Romano G, Galasso R, et al. Should we continue to study high-dose chemotherapy in metastatic breast cancer patients? A critical review of the published data. Bone Marrow Transplant 2003;31:525-30.
10. Lum LG, Sen M. Activated T-cell bispecific antibody immunotherapy for high-risk breast cancer: bench to bedside. Acta Haematol 2001;105:130-6.